Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	September 12, 2024
Length of Meeting:	2 hours and 26 minutes
Location of Meeting:	DMAS Board Room 102

Members Present:
Rachel Cain, PharmD, Chair
Elizabeth Gaughan, MD, Vice-Chair
Denese Gomes, NP
Jack Weisskohl, NP
Melissa Chouinard, MD
Seth Brant, MD
Denise Lowe, PharmD

Members Not Present:
Kristi Fowler, RPh
Michele Thomas, PharmD
Wendy Nash, PharmD

DMAS Attendees:
MaryAnn McNeil, RPh, Pharmacy Manager
JoeMichael Fusco, PharmD, MCO Pharmacy Compliance Manager
Arielle Abbate, PharmD, Pharmacy Policy Analyst
Kiara Jasper, MHA, CPhT, Pharmacy Systems Administrator

Contractors:
David D'Amico, PharmD, Director, Clinical Account Services, Prime Therapeutics
Nancy Eldin, PharmD, Pharmacist Account Executive, Prime Therapeutics
Matthew Estes, PharmD, Pharmacist Account Executive, Prime Therapeutics
Jeni Hodzic, CPhT, Senior Account Management Specialist, Prime Therapeutics

Visitors:
Bill Tassone
Brian Trentler
Caroline Faber
Charles Aiken
Dan Shappee
Doug Welch
Heidi Dix
Joe Kupiec
Karen Franks
Laurie Mauthe
Lisa Barefoot
Lori Stalker

Mark Vaughan
Mischa Agster
Rob Berringer
Sarah Bristol
Scott Burns

Call to Order and Introductions

Dr. Rachel Cain welcomed and thanked everyone for attending the DUR meeting.

Dr. Cain called the meeting to order at 1:22 pm. She announced that the DUR Board has three vacancies, two of which are physician positions, and one is a pharmacist position representing the chain drug stores.

Minutes – June 13, 2024

Jack Weisskohl motioned to approve the June 13, 2024, meeting minutes as submitted. Dr. Elizabeth Gaughan seconded the motion.

New Drugs

The DUR Board reviewed Alvaiz™ (eltrombopag choline), Fabhalta® (iptacopan), Filsuvez® (birch triterpenes), Rezdiffra™ (resmetiron), Rivfloza™ (nedosiran), Voydeya™ (danicopan) and Zilbrysq® (zilucoplan). The Impact Reports and the report for the utilization of these seven new DUR drugs for Fee-For-Service (FFS) and Managed Care Organizations (MCOs) were reviewed.

The DUR Board reviewed the current service authorization (SA) criteria for Promacta®. After discussion by the board, Denese Gomes motioned to accept the form with the following updates: add Alvaiz™ to the SA criteria along with the FDA approved indications and minimum age; add the question “has the patient had a baseline ocular exam prior to therapy?” for both Alvaiz and Promacta set of criteria questions; add the question “will sexually active individuals of reproductive potential use effective contraception during treatment and for at least 7 days after stopping treatment?” for both the Alvaiz and Promacta set of criteria questions; strike “an adult and” from questions 2 and 4. Dr. Denise Lowe seconded the motion.

The DUR Board reviewed the monograph and the Risk Evaluation and Mitigation Strategy (REMS) information for Fabhalta®.

The DUR Board reviewed the SA criteria for Filsuvez®. After discussion by the board, Dr. Melissa Chouinard motioned to accept the SA criteria with Questions 1 and 8 removed. Dr. Gaughan seconded the motion.

The DUR Board reviewed the SA criteria for Rezdiffra™. Updates to the form proposed by the board included: changing nomenclature of "NASH" to "MASH", adding questions pertaining to exclusion criteria from the clinical trial for Rezdiffra™, and removing questions 4 and 9. On question 3, bullet 3, the board discussed taking "past two years" off the form for the qualifier of the patient having a prior liver biopsy and adding that the liver biopsy shows Stage1B, 2 or 3 fibrosis. It was also proposed by the board that question 5 be updated to more accurately reflect the package insert with a statement "patient has been counseled on diet and exercise". Prime will check on weight loss surgery and GLP-1 utilization to determine if these are true contraindications. Lastly, the board proposed removing bullet 3 from question number 6, "Any other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis) from the form. With the number of proposed changes to this SA form, voting on the form was tabled until the next DUR Board meeting.

The DUR Board reviewed the SA form for Rivfloza™. The board proposed removing question 10, and updating question 6 to state "Has the member received a kidney or liver transplant?". Dr. Chouinard motioned to approve the SA criteria with these changes. Ms. Gomes seconded the motion.

The DUR Board reviewed the prescribing information for Voydeya™ and Zilbrysq®, as well as the REMS information regarding these two new drugs.

DUR Quarterly Newsletter - The June 2024 DUR Quarterly Newsletter was available in the DUR binder for review.

Topics for Discussion

Synagis® – The DUR Board reviewed current guidance for Synagis® usage, along with utilization during the 2023 RSV season (October 1, 2023 – March 31, 2024). Two members were denied coverage requests during the 2023 season, and the Board reviewed these denials. The Board also reviewed SA criteria for Synagis®. The SA form was updated to reflect the 2024 season (October 1, 2024 – March 31, 2025), the change in name for the pharmacy benefit vendor from Magellan Rx Management to Prime Therapeutics, and to update revision dates. Ms. Gomes motioned to accept the SA criteria with these changes. Dr. Seth Brant seconded the motion.

Antipsychotic Medications in Children – The DUR Board reviewed Antipsychotic Medications in Children reports for FFS and MCOs. A behavioral therapies summary was included in this data, and ICD10 data was also included for the five youngest FFS members. Dr. Cain agreed to follow up with the provider for one of these FFS members that did not show any behavioral therapies listed. Dr. Chouinard requested that the vendor and DMAS investigate an MCO member showing in the utilization data with an age of 0.

Antidepressant Medications in Children – The DUR Board reviewed Antidepressant Medications in Children reports for FFS and MCOs. A behavioral therapies summary was included in this data, and ICD10 data was also included for the five youngest FFS members. Ms. Gomes suggested that DMAS contact the provider of members using trazodone at an age less than the FDA approved labeling.

Mood Stabilizer Medications in Children – The DUR Board reviewed Mood Stabilizer Medications in Children reports for FFS and MCOs. A behavioral therapies summary was included in this data, and ICD10 data was also included for the five youngest FFS members. The board discussed FFS member number 5, and suggested DMAS look further into this member's utilization of a mood stabilizer without qualifying diagnoses. Dr. Cain suggested that DMAS follow up with a pediatric psychiatrist or with the physician of this member.

Overlaps in Antipsychotics, Antidepressants and Mood Stabilizers in Children – The DUR Board reviewed Overlaps in Antipsychotics, Antidepressants and Mood Stabilizers in Children reports for FFS and MCOs. A behavioral therapies summary was included in this data, and ICD10 data was also included for the five youngest FFS members.

Reports

ProDUR

The DUR Board reviewed and discussed the ProDUR reports for the previous two quarters. The DUR Board reviewed the new ProDUR Top Encounters by Problem Type – Severity 1, Severity 2 and Severity 3 reports. In the March 2024 meeting, the Board requested a list of alerts that could possibly be turned off. The Board reviewed these lower severity alerts and agreed that they should follow the industry standard and leave these lower severity alerts active.

RetroDUR

I. Recent RetroDUR Activity

The DUR Board reviewed the Recent RetroDUR Activity reports. This included the RetroDUR activity response page along with the RetroDUR letter.

II. RetroDUR Criteria Estimates

The DUR Board reviewed the Criteria Exception Estimates Reports. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment Amount for FFS and each individual MCO plan.

Utilization Analysis

The DUR Board reviewed the Utilization Analysis reports. The board had previously requested to identify and label the preferred and non-preferred drugs on the Top 25 Drugs Ranked reports. Preferred drugs were shown in red.

Next DUR Meeting

December 12, 2024

Dr. Chouinard motioned to adjourn the meeting. Dr. Gaughan seconded the motion.

Meeting adjourned at 3:48 pm